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Abstract: Drug-facilitated sexual assault (DFSA) investigations can be hindered by 
delayed reporting or victim unwillingness to fully participate in a physical examination. 
In turn, biological evidence collected to prove incapacitation at the time of the incident 
can be difficult to obtain. Sweat was evaluated as a specimen type for confirmation of 
DFSA agents. A methanol extraction paired with qualitative liquid chromatography-
tandem mass spectrometry (LC/MS/MS) analysis was developed and validated for the 
analysis of sweat patches. Eight sedatives that are commonly-encountered in DFSA cases 
were included in the method panel. In addition, a preliminary study was completed to 
assess the effectiveness of sweat patches in practical DFSA situations. One subject took 
50 mg diphenhydramine and sweat patches were applied upon dosing, after 1 d, and after 
3 d to simulate delayed reporting. Sweat patches were compared to urine samples taken at 
1 d, 3 d, and 7 d to evaluate differences between specimens. Method validation 
successfully characterized limit of detection, carryover, interference, matrix effects, and 
stability. All sweat patch samples from the preliminary study, including those with 
delayed application, contained detectable diphenhydramine in an amount > 0.75 ng/patch, 
while only the urine sample taken at 1 d contained > 7.5 ng/mL diphenhydramine. These 
results suggest that sweat may be more effective than urine for the detection of some 
DFSA compounds in cases of delayed reporting. As noninvasive and cumulative 
collection devices, sweat patches may prove to be appealing to both toxicologists and 
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 Drug-facilitated sexual assault (DFSA) is the abuse of drugs or alcohol to perform 
nonconsensual sexual acts on an incapacitated victim.1 Legal definitions vary by jurisdiction but 
generally include a broad spectrum of sexual offenses, ranging from intimate touching to forcible 
rape. The central characteristic in DFSA is victim incapacitation – a factor which complicates 
reporting, evidence collection, laboratory analysis, and criminal prosecution. With no universal 
definition, the term “incapacitation” also lends itself to interpretation, but is typically defined as 
the inability to express consent due to the influence of drugs or alcohol. DFSA victims describe 
drug-induced incapacitation as paralysis accompanied by flashes of intermittent consciousness or 
complete blackout.1 
 Sweat has been identified as a potential sample matrix for the detection of DFSA agents 
due to its noninvasiveness and potential to extend detection times. This project examines if sweat 
qualifies as a viable specimen type for toxicological analysis in DFSA investigations. First, a 
review of literature will give background information about DFSA, describe the drugs to be 
included in the panel, offer insight about the elution of drugs into sweat, and provide an overview 
of current DFSA instrumental drug analyses. An extraction procedure and liquid 
chromatography-tandem mass spectrometry (LC/MS/MS) detection method containing detailed 
instructions and parameters will then be presented. Data from the method validation and a  
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preliminary study will be shown. Finally, discussion on the practicality and implementation of 
sweat patches as a means of DFSA testing are presented.    







2.1 Background  
2.1.1 Drug-Facilitated Crimes 
 DFSA is just one of many types of drug-facilitated crime (DFC); others include robbery, 
homicide, kidnapping, mental manipulation, and maltreatment.2 Although DFSA is believed to 
comprise of the majority of DFCs in the United States, other DFCs remain prominent in other 
areas of the world. A French study concluded that only 46% of DFCs were isolated DFSAs and as 
many as 22% were isolated robberies.2 Although this research will primarily focus on DFSA, 
many ideas presented here can be applied to both DFSAs and DFCs due to the inherent 
similarities of the crimes. 
2.1.2 History 
 Anecdotes of DFCs date to the early twentieth century, most notably with bartender 
Mickey Finn and the Lone Star Saloon in Chicago, Illinois. Finn was alleged to have spiked 
customers’ drinks with chloral hydrate in order to draw them into an easy theft.3 DFSAs received 
little attention until the late 1990s when the notoriety of fast-acting sedatives like flunitrazepam 
(Rohypnol®) and γ-hydroxybutyric acid (GHB) thrust the crime into the spotlight. 
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2.1.3 Methods of Administration  
 Drug administration in DFSA cases can be classified into three categories: surreptitious, 
voluntary, and misrepresentative.1 Each method carries unique significance in the laboratory and 
the courtroom. Surreptitious administration occurs when an offender covertly administers a drug 
to a victim without the knowledge or consent of the latter. Media and society perpetuate this 
image as the prototypical scenario of DFSA, yet a U.S. Department of Justice study concluded 
that only 6 out of 144 sexual assault complainants (4.2%) were given a drug surreptitiously.4 In 
contrast, voluntary drug consumption occurs with the intent of intoxication by the victim. The 
widespread recreational consumption of ethanol has staged the drug to be the most prominent 
enabler of DFSA and is present in as high as two-thirds of DFSA cases.5 Finally, 
misrepresentative administration occurs when an offender lies about a drug that the victim uses 
voluntarily. Using this technique, an offender can discreetly increase the concentration of an 
alcoholic drink or falsify the identity of a victim’s medication. 
2.1.4 Approaches 
 In combination with the three methods of administration, offenders use one of two 
general approaches to commit DFSAs: proactive and opportunistic.6 A DFSA in which the 
offender has the deliberate intent to incapacitate and assault the victim is considered proactive. 
Proactive DFSAs are premeditated and more likely to be surreptitious or misrepresentative in 
nature. In contrast, an opportunistic DFSA occurs when an offender spontaneously takes 
advantage of a victim’s compromised physical or mental state. Opportunistic DFSAs are more 
commonly associated with voluntary drug use by the victim. 
2.1.5 Settings 
 Parties and nightclubs are publicized as stereotypical settings for DFSAs, but a number of 
unsuspecting locations can also host the crime. These include offices, homes, schools, health care 
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facilities, restaurants, and parks.7 Offenders look to establish and maintain control of the setting, 
isolate the victim, and ensure drug administration. One law enforcement training manual 
identified three potential crime scenes for DFSAs: the site where the drug was bought or 
manufactured, the site where the drug was ingested, and the site where the victim was sexually 
assaulted.8 
2.1.6 Prevalence/Reporting 
 The significance of DFSA lies within the number of incidents – that is, if there exists a 
proper method of assessment. The prevalence of incapacitation with drugs or alcohol has been 
cited anywhere from 7 to 35% of all sexual assaults.4,9 Other experiments claim incidence of 
drug- or alcohol-positive victim samples as high as 60% in sexual assaults suspected of drug 
involvement.10 DFSA is a difficult crime to accurately quantify for several reasons. The lack of 
standardization among definitions and data collection techniques complicates the application and 
interpretation of statistical analyses. In addition, it is unclear whether any given surge of cases is 
due to an actual increase in prevalence or simply a rise in awareness, advances in laboratory 
research, and/or successful prosecution.11 
 Underreporting also plagues the legitimacy of estimates. This phenomenon, already well-
established in traditional sexual assaults, is believed to be even more pervasive in DFSAs. 
Admitting to voluntary drug use may feel self-incriminating to victims, especially in cases 
involving illicit drugs or underage users, and discourage reporting. Debilitating residual effects of 
a drug may endure over time after an assault, preventing the victim from recalling important 
details about the incident such as the identity of the offender or the timeline of events. These 
lasting effects may also leave victims in a physical state that renders them unable to report the 
crime until they have fully recovered. 
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 Psychological sequelae are thought to be large contributors to victims’ underreporting of 
DFSAs. Anterograde amnesia may impede the recollection of critical details about the offender’s 
identity or actions, precluding the ability of the victim to speak out. Victims may feel that their 
trauma would be re-aggravated by unrelenting interrogation in police interviews, courtroom 
testimonies, and therapy sessions. The sense of powerlessness experienced during a DFSA may 
carry over to the hours, days, and weeks following the crime and discourage the victim from 
pursuing medical treatment or legal action. 
 In addition to the unique circumstances presented above, DFSA victims share many of 
the consequences experienced by victims of traditional sexual assaults. Feelings of guilt or self-
blame may arise and persuade the victim to second-guess the cause of the assault. Similarly, the 
victim can downplay the physical or emotional impact of the event. The fear of retaliation or 
repetition by the offender may persist as a constant threat. Post-traumatic stress disorder, 
depression, and substance abuse may develop as a result of victimization.12 
 Delayed reporting in DFSA cases presents a multitude of challenges to investigators and 
forensic scientists. The victim’s memory may become unreliable as time elapses after the assault, 
especially if recollection is impaired by drug effects or emotional trauma. The physical 
examination becomes less effective as wounds heal or evidence is removed. Toxicological testing 
loses value if the delay in reporting exceeds a drug’s residence within the body.   
 DFSA victims may also fear accusations of false reporting, a common argument of 
defense attorneys. False reporting for traditional sexual assaults are estimated to have an 
incidence rate of 2-8%.13 The unique circumstances of DFSAs, especially cases involving 
voluntary drug use, give defense attorneys the opportunity to question a victim’s character.  
 Victim credibility is a major source of debate throughout any sexual assault case. A 
victim is often the only witness and may carry perceived or actual bias. Drug use can be argued to 
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link to “risky” behavior, and proof of drug ingestion – even if administered surreptitiously – may 
taint the victim’s innocence. Cognitive impairment and amnesic effects caused by DFSA drugs 
may reduce the accuracy of a victim’s statements about the incident in the eyes of a judge or jury. 
 Even if victims overcome these obstacles, sexual assault cases have infamously low 
success in the criminal justice system. In fact, two of the main setbacks encountered in sexual 
assault prosecution are particularly relevant to DFSAs.14 First, alcohol use by the victim prior to 
the assault decreases the likelihood that the case will be prosecuted. Second, as the time interval 
between the assault and the forensic medical examination increases, the likelihood that the case 
will progress through the legal system decreases. Conclusive evidence of victim incapacitation, 
such as toxicological evidence, can serve as a strong counterpoint to these attacks. 
2.1.7 Sample Collection/Testing 
 Effective initiatives in forensic nursing are designed to balance comprehensive patient 
care with proper evidence collection in sexual assault cases. The development of the Sexual 
Assault Nurse Examiner (SANE) position exemplifies this revolution. SANEs provide sexual 
assault victims with injury treatment, emotional support, and referral to other aid services. In 
addition, SANEs supply evidence to police and prosecutors and can testify in court as an expert 
witness. The implementation of a SANE program within a community is proven to advance 
sexual assault cases to higher levels of deposition.14 Still, the absence of information in DFSA 
cases places a significant weight on evidence that is available and biological evidence can quickly 
become a high priority. 
 The use of evidence collection kits is standard in many SANE examinations. The exact 
content of a kit may vary by jurisdiction, but evidence items generally include blood, oral fluid, 
head hair, pubic hair, fingernail debris, swabs from genitalia, and clothing. SANEs may also 
request a urine sample if drug use by the victim is admitted or suspected. 
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 The collection of these evidence types can be invasive and demanding, and victims may 
refuse some of the samples to be taken. As a result, investigators may be denied a critical piece of 
information to substantiate the victim’s claim. In addition, blood and urine – the traditional 
sample matrices in which DFSA testing is conducted – are only feasible for drug analysis within 
hours or days of exposure.15 If collected at a later time, any remnants of a DFSA dose may be 
fully metabolized or excreted. 
 Given the widespread prevalence of DFSA and the relatively low rates of reporting and 
prosecution, problems like examination invasiveness force SANEs, investigators, and forensic 
scientists to seek alternative methods for victim support.  
2.2 Alternative Sampling 
 The lack of peer-reviewed research is currently a limitation to alternative specimen 
assessment. Workplace drug testing, which has many similarities to forensic drug testing, has not 
yet validated alternative specimen testing to achieve the same level of confidence that a urine test 
provides. A 2008 publication by the U.S. Department of Health and Human Services stated that 
additional research is needed for sweat, hair, and oral fluid analysis for the testing to become 
standalone instead of merely supplemental.16 
 Still, the potential of alternative specimens has caused forensic laboratories to consider 
developing new methods to utilize their advantages. In fact, the United Nations Office on Drugs 
and Crime recently published guidelines for sweat, hair, and oral fluid laboratory techniques in an 
effort to standardize international practices.17 The restrictions that accompany the analysis of 
DFSA samples cannot be ignored, but a more detailed investigation into the intricacies of sweat 





2.3 Sweat Sampling/Methods 
 Like other specimens collected for forensic analyses, sweat contains drugs and 
metabolites that are present in the body. The pathway of a drug’s excretion in sweat is not yet 
completely understood. Factors such as sweat pH, rate of diffusion, and rate of perspiration are 
thought to affect the volume and composition of excreted sweat.18 Passive diffusion from 
capillaries into sweat glands or migration from interstitial fluid to the skin surface are thought to 
be the primary pathway of drugs’ incorporation into sweat.19,20 The former process should be 
particularly favorable for lipid-soluble, basic substances due to blood’s high pH in relation to 
sweat. The latter process involves migration across subcutaneous fat and fascia as well as the 
dermis, epidermis, and stratum corneum, where the compounds would be readily dissolved in 
eccrine and apocrine secretions. Little is known of many drugs’ potential interaction with other 
components of the skin such as hair follicles, sebaceous glands, nerve fibers, and connective 
tissue. Overall, as long as the distribution mechanism of drugs in sweat remains a mystery, only 
limited conclusions can be made on the subject. 
 Next, sweat must be effectively transferred from the skin to the sweat patch. Sweat 
patches are typically manufactured with a large adhesive surrounding an absorption pad, similar 
to a bandage. The area of patch application may affect sweat collection; different areas feature 
different secretion rates and chemical constituents.21 Pharmchem Inc., a prominent supplier of 
sweat patches, suggests application in an area that is free of hair/scars/open wounds, is not 
exposed to excessive skin flexing or wrinkling, and has minimal contact with clothing.22 For these 
reasons, the company advocates the dorsal upper arm as a primary application site and the lower 
torso or lower back as backup sites.22 Each of the proposed areas has moderate eccrine sweat 
gland density and secretion relative to others.21 Sweat collection with a patch is cumulative during 
the time of patch wear. Pharmchem recommends a wear time of greater than 24 hours in order to 
obtain an adequate sample.22  
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 The volume of sweat collected with a patch is currently unknown; however, Appenzeller 
et al used a similar collection device on 25 subjects and collected volumes ranging from 0.45 to 
3.8 mL.23 This study also suggests that sodium may be viable as an internal standard within the 
sweat sample to accurately quantify other analytes.23 The possibility of drug transfer from the 
absorption pad back to the skin has been postulated as a cause for concentration decrease in 
patches worn for long periods of time.24 A means to reduce or remove equilibration, such as a 
one-way absorption mechanism, may prove useful to combat this problem. Uemura et al 
concluded that toxicological results obtained from sweat patch analysis may be affected length of 
the collection period, the location of the patch placement on the body, and the potential of drug 
reabsorption from the patch back to the skin.25 Despite variable sweat volumes and possible 
redistribution back onto the skin, potential issues can be reduced with proper use of the patch. 
 Still, sweat analysis needs to overcome those barriers to become independent of other 
testing. DFSA victims that wear the patch should expect that the results will hold in court; after 
all, it may be the only viable item of evidence to prove intoxication at the time of the incident. 
Therefore, the development of an accurate confirmatory method that boasts detection of several 
common DFSA-related drugs and metabolites with high sensitivity is vital. To do so, valuable 
information must be drawn from previously-published methods in sweat analysis. 
 Research in sweat patch analysis fluctuates considerably in methodology due to the youth 
of the specialty and the lack of standardization. The first variable is specimen collection. When 
available, clinical subjects can be recruited to simulate actual patch application, wear, and 
removal. This approach incorporates many variables of realistic sweat collection but is far less 
controlled than a pure laboratory experiment. Studies investigating interindividual differences in 
drug distribution to sweat or potential effects of patch wear would benefit from clinical sampling 
the most. If subjects are unavailable, researchers may employ the use of artificial sweat that 
contains an approximate concentration of the most common or most significant compounds in 
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sweat.26 In these experiments, drugs are mixed with the artificial sweat and injected into the 
patch, or the patch is submerged directly into the mixture. Artificial sweat is well-suited for 
refining method procedures, such as extraction techniques or detection parameters, due to its 
availability and reproducibility relative to natural sweat.  
 Patches with either real or artificial sweat then undergo an extraction procedure. This 
process is completed to isolate the drugs that are to be detected; any extraneous compounds that 
remain in solution upon analysis may complicate or interfere with the analytes of interest. The 
most common extraction approach for sweat patches is solid-phase extraction, which separates 
components of a sample using a column with specific physical and chemical properties.27 Minor 
parameters, like the composition of extraction buffer or sequence of column preconditioning, may 
be modified depending on the goals of the experiment. In a variation on extraction technique, De 
Martinis et al describe a disk solid phase extraction for amphetamines.27 Effective extraction is 
important for a matrix like sweat because samples are typically low in volume and may contain 
many impurities. 
 Following isolation of the analytes of interest, gas chromatography-mass spectrometry 
(GC/MS) and liquid chromatography-tandem mass spectrometry (LC/MS/MS) are the standard 
methods of analyte separation and detection for confirmatory sweat patch testing. The goal of this 
portion of the method is to optimize for high sensitivity in anticipation of the low drug amounts 
that are expected to appear in sweat patches. Quantification of drug concentration in sweat does 
not currently represent a meaningful correlation to physiological symptoms or concentrations in 
other biological fluids, but more exact results can potentially lay the foundation for such 
relationships. 
 Sweat patch research has been completed for many different classes and types of drugs. 
Fay et al successfully detected amphetamines in sweat patches by immunoassay and GC/MS.28 In 
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this study, one notable finding is that two potential adulterants, tile cleaner and cough syrup, 
caused a false-positive result by immunoassay. Similar research by Kintz & Samyn and Barnes et 
al revealed that MDMA and metabolites are present in sweat patches worn by recreational ecstasy 
users.29,30 Brunet et al quantified methadone, heroin, cocaine and metabolites in sweat using solid-
phase extraction coupled with GC/MS.31 Huestis et al explored the disposition of Δ9-
tetrahydrocannabinol (THC) in the sweat of cannabis users.32 Data from this experiment 
suggested that daily cannabis users remained above 0.4 ng/patch for up to four weeks following 
cessation and naïve cannabis users administered 14.8 mg THC/day for five consecutive days did 
not produce a positive sample. 
 The circumstances of the victim’s drug usage may also affect sweat patch analysis. 
Environmental contamination of drugs present on the skin prior to application of the patch is 
possible.33 One-time drug exposure may yield low concentrations in sweat, sometimes below the 
limit of detection of analytical instruments. Chronic drug exposure, on the other hand, may yield 
higher concentrations in sweat but complicates the landscape of proving drug use in a specific 
DFSA incident. Adulteration, another potential source of contamination, is referred only in 
manufacturer instructions by the visual inspection of the patch upon removal.22 Perhaps the 
reason that tampering is not addressed in research is because sweat patch testing is not prevalent; 
if this specimen type increases in popularity, more attempts will surely to be made to bypass 
detection. 
 Regardless of drug type or usage conditions, research that specifically addresses DFSA 
will provide more practical benefit to toxicologists than interpreting results from general research. 
Only one method discovered during literature review utilized sweat sampling associated with 
DFSA. Demoranville & Verkouteren developed a panel including GHB, ketamine, flunitrazepam, 
cocaine, MDMA, and metabolites.34 The experiment featured simulated sweat as a specimen 
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matrix and ion mobility spectroscopy (IMS) for detection. The authors concluded that IMS was a 
valid initial screen for the analytes under investigation. 
 Other methods utilize sweat as a specimen type, but do not employ long-term sweat 
patches as a collection device. Huestis et al evaluated the disposition of cocaine, codeine, and 
metabolites in sweat using heat-induced stimulation of the palm and torso.20 Specialized “fast 
patches”, designed for only 30 minutes of wear, were compared against traditional sweat patches. 
“Fast patches” were found to contain greater concentrations of analytes than traditional sweat 
patches.  
 Abanades et al compared a cotton wipe of the armpit and forehead to traditional sweat 
patch sampling of clinical subjects exposed to GHB.35 The authors concluded that the variability 
of GHB concentrations seen in both wipes and patches rendered the analysis unsuitable for 
practical use. In another study, cotton wipes were used on the forehead to detect MDMA 5 h 
following administration.36 Average sweat concentrations remained below 25 ng/wipe. Similarly, 
Pichini et al administered single doses of MDMA to subjects and compared armpit wipes to sweat 
patches via immunoassay and GC/MS; the research concluded that both were viable within 24 h 
of administration, but the authors acknowledged that the results were preliminary for application 
across a full range of toxicological substances.24 Sweat wipes have also been explored as a viable 
sampling technique for drivers under the influence of a drug other than alcohol.37 Variability and 
the risk of contamination in uncontrolled wipe studies are believed to be high, especially in cases 
of repeated dosing or external contact with areas to be wiped. 
2.4 DFSA-Related Drugs 
 To a DFSA offender, an ideal drug to deploy on a victim will be easy to obtain and 
administer. The drug must sedate the victim quickly and effectively, complete with 
pharmacological effects to disrupt the victim’s ability to resist force or remember the assault. 
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Many drugs and drug classes meet these qualifications, but only the classes utilized in this 
research will be described below. Notable omissions include ethanol, marijuana, barbiturates, 
GHB, ketamine, cocaine, and amphetamines. 
 Benzodiazepines are a therapeutic drug class that are commonly used as prescription 
anxiolytics, anticonvulsants, muscle relaxants, pre-anesthetics, and hypnotics.38,39 Absorption 
rates of the class are variable; however, activity may be expedited if the drug is already in 
solution (i.e. mixture into an alcoholic drink).38 In addition, metabolism is complex and extensive, 
and the presence or absence of certain metabolites can be different among matrices.38 
Benzodiazepines act as central nervous system (CNS) depressants by binding to receptors on 
gamma-amino butyric acid (GABAA). Once the drug is bound, the inhibitory effects of GABAA 
are potentiated and cause sedation.38,39 In combination with illicit drugs, benzodiazepines 
minimize the effects of dangerous highs and withdrawal symptoms.38,39 This interaction increases 
abuse potential and establishes the drug class as a popular choice among recreational and chronic 
users. Rapid onset of action and user symptoms of sedation, amnesia, and impaired judgment are 
characteristics of benzodiazepines that appeal to DFSA offenders.39 
 Opioids are therapeutic analgesics primarily intended for pain management, but can also 
serve as surgical anesthetics and cancer treatment medications.40 Opioids act on opioid receptors 
in the central and peripheral nervous systems to induce drowsiness, muscle relaxation, and a 
decreased sensation to pain.40 Despite strict government regulation, opioids are prevalent and can 
be obtained from doctor’s offices, dental suites, veterinary facilities, hospitals, pharmacies, and 
the black market. Symptoms of particular interest to DFSA offenders include amnesia, impaired 
cognitive function, and loss of consciousness.40 Co-administration of ethanol enhances the 
sedative effects of many opioids.41  
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 Opioids were one of the first drug classes to be tested using sweat patches, done so as 
early as 1996, and were originally explored to assess practicality in the monitoring of abusers.42 
Huestis et al detected heroin, 6-acetylmorphine, morphine, and codeine in sweat samples from 
clinical trial subjects at levels of 10 ng/mL using enzyme-linked immunosorbent assay (ELISA) 
and 5 ng/mL using GC/MS.43 Similarly, Concheiro et al detected buprenorphine, methadone, 
heroin, morphine, codeine, and metabolites in sweat as low as 1 ng/patch via LC/MS/MS.26 
 Antihistamines are a class of over-the-counter medications designed to regulate the 
versatile compound histamine. The role of histamine includes allergic response, fluid secretion in 
the stomach, regulation of appetite and alertness via the CNS, contraction of muscle cells in 
pulmonary and gastrointestinal systems, and relaxation of small blood vessels.44 Drugs in this 
class are antagonists to histamine receptors located in smooth muscle, cardiac muscle, gastric 
parietal cells, the CNS, endothelial cells, and hematopoietic cells.45 An adverse side effect in first-
generation histamines is moderate sedation, which has since been corrected in modern 
formulations. Still, first-generation antihistamines remain available on the open market. From a 
DFSA perspective, antihistamines are dangerous due to the onset of CNS depression, slowed 
response, reduced attention, and drowsiness.44 Anticholinergic effects such as confusion, blurred 
vision, and lightheadedness can also be demonstrated after antihistamine use.45 Interaction with 
ethanol, benzodiazepines, and other depressants is additive and intensifies sedation.45 The 
extensive availability, hypnotic pharmacological response, rapid onset of activity (15-60 min), 
and moderate duration of action (4-8 h) primes antihistamines for use in DFSAs.45 
 Antidepressants are medications prescribed by clinicians to treat mental conditions like 
depression or panic disorders. Tricyclic antidepressants (TCAs), one of the oldest subgroups of 
the drug class, are the most relevant to DFSA. TCAs exert their intended effect by inhibiting 
reuptake of serotonin and norepinephrine but also interact with adrenergic, muscarinic, and 
histamine receptors to produce unwanted side effects on a variety of physiological systems.46 
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TCAs slow the depolarization of cardiac action potentials, ultimately leading to hypotension and 
cardiac arrhythmia.41 Anticholinergic effects such as blurred vision and cognitive impairment can 
manifest.41 CNS effects include confusion, hallucinations, and drowsiness.46 In the presence of 
ethanol, TCA concentration in blood is found to be markedly increased.46 TCAs generally have a 
long onset of action (4-8 h), but DFSA offenders can counteract this phenomenon by deploying a 
large single dose or exploiting interaction with another sedative.46 
 “Z-drugs” (zolpidem, zopiclone, and zaleplon) are novel sedatives designed to treat short-
term insomnia. Z-drugs have pharmacology similar to benzodiazepines but bind more selectively 
to the GABAA sites that regulate sleep induction.47-49 The primary effect of Z-drugs is sedation 
but hallucinations, indigestion, headache, and nausea have also been reported.48 The use of some 
Z-drugs causes significant residual effects such as a hangover.47 The ability of Z-drugs to induce 
and maintain a strong sedation along with the amnesic properties of the class make them 
attractive candidates for DFSA offenders. Z-drugs have been successfully quantified in blood, 
urine, oral fluid, and hair, but have not yet been explored in sweat.50 Leloup et al published an 
LC/MS/MS method for the detection of benzodiazepines and Z-drugs in blood, urine, and hair.51 
 Drug deployment in DFSA is not limited by class or desired effect; in theory, any drug 
that exerts a significant impact on one’s mind or body can qualify. In 2014, the Society of 
Forensic Toxicologists issued a list of recommended detection limits for as many as 104 drugs 
and metabolites that were commonly encountered in DFCs.52 Adamowicz & Kala published a 
GC/MS method that screens for 128 DFC-related compounds in urine.53 
2.5 Conclusion 
 Alternative specimen types are being explored for unique or specific applications. One 
such application is the deployment of sweat patches to detect drugs of abuse. Drug disposition 
into sweat is currently under investigation, but recent discoveries lend insight into possible 
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mechanisms of interaction. Volume variability, drug reabsorption, and environmental 
contamination remain as possible flaws in an otherwise effective collection device. Common 
analytical techniques are customized to address the unique characteristics of the matrix. Sweat 
patches have proven successful for the detection of numerous drug classes thus far, leading to the 
hypothesis that DFSA sedatives will be no different. An additional element to the current research 
– a preliminary study with a focus on DFSA – provides a novel and practical application to 









 This section outlines the validation and preliminary study protocols used in this research. 
Descriptions of standard preparation, extraction technique, and instrument setup are provided. 
Validation requirements for a qualitative method are defined and applied to the current project. 
Management of preliminary study sampling is detailed. Procedures were developed with input 
from the Federal Bureau of Investigation Laboratory.  
3.2 Materials 
 The materials required for this experiment include reference standards, sweat patches, 
reagents, and miscellaneous lab supplies. All reference standards were obtained from Cerilliant® 
(Round Rock, TX). Sweat patches are Pharmchek® Sweat Patches obtained from PharmChem, 
Inc. (Fort Worth, TX). Chemicals, laboratory-grade reagents and miscellaneous laboratory 
supplies were obtained from VWR International® (Radnor, PA). SMx™ blank sweat and blank 
urine were obtained from UTAK Laboratories (Valencia, CA). 
3.3 Drug Panel 
 Eight analytes were chosen by the research team as prominent or emerging drugs in 
current DFSA casework. The panel contains three benzodiazepines (alprazolam, clonazepam, 
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diazepam), two opioids (fentanyl, hydrocodone), one antihistamine (diphenhydramine), one 
antidepressant (nortriptyline), and one Z-drug (zolpidem). 
 Solutions containing all analyte compounds were produced from certified reference 
standards in methanol at high, medium, and low concentrations. When used for method validation 
or comparison for preliminary samples, control solutions were added to the absorbent pad of the 
sweat patch at a volume of 100 μL. The amount of each analyte following 100 μL addition of 
control solution to a patch is also displayed in Table 1, listed in ng/patch. 
Table 1. Analyte Amounts Per Patch Upon Addition of 100 μL Control Solution 
Analyte High Control Medium Control Low Control 
 (ng/patch) (ng/patch) (ng/patch) 
Alprazolam 100 10 3 
Clonazepam 25 2.5 0.75 
Diazepam 100 10 3 
Diphenhydramine 25 2.5 0.75 
Fentanyl 100 10 3 
Hydrocodone 25 2.5 0.75 
Nortriptyline 25 2.5 0.75 
Zolpidem 25 2.5 0.75 
  
 Deuterated internal standards were added to controls and samples to minimize variances 
in analysis processes. One deuterated internal standard was included for each respective analyte, 
displayed below in Table 2. A stock internal standard mix was produced in methanol at a 






Table 2. Analyte and Internal Standard Pairings 











 Sweat patches were placed in a fume hood to air-dry for 30 min. The absorbent pad was 
removed from each patch using disposable tweezers, folded, and placed into a 7 mL test tube. 50 
μL of internal standard mix was added to each test tube. Four mL of methanol was then added to 
each test tube. Test tubes were briefly hand-shaken and inverted to ensure complete saturation of 
all areas of the patch. Using an automated 5 mL glass pipette, 2.5 mL of solution was withdrawn 
from each test tube and deposited into another test tube. Test tubes containing patches and 
remaining solutions were discarded.  
 Withdrawn solutions were placed in a sample concentrator using nitrogen gas at 40°C 
until solutions had completely evaporated. Samples were then reconstituted with 150 μL of 
solution containing 65% aqueous mobile phase and 35% organic mobile phase (described in 
Section 3.5). Reconstituted solutions were mixed, vortexed, and transferred to 1 mL LC/MS/MS 





3.5 Instrument Parameters 
 All samples were run on a Shimadzu 8040 LC/MS/MS system equipped with 2 LC-20AD 
solvent pumps, an SIL-20AC HT autosampler, a CTO-20A column oven, a CBM-20A control 
module, an FCV-20AH2 diverter valve, and a triple quadrupole mass spectrometer.. Aqueous 
mobile phase, consisting of 2 mM ammonium formate and 0.1% formic acid in water, and 
organic mobile phase, consisting of 2 mM ammonium formate and 0.1% formic acid in methanol, 
were used in gradient to move the samples through the column at a total flow rate of 0.35 
mL/min. The column used was a Restek® 2.7 μm Raptor™ 50 x 2.1 mm column with an attached 
guard cartridge to increase durability. The mass spectrometer used electrospray ionization and 
operated in positive ion mode. Injection volume of each sample was 10 μL.  
 Multiple reaction monitoring (MRM) was used to enhance detection and identification of 
precursor and product ions. Retention times and two sets of MRM transitions were individually 




Table 3. Analyte and Internal Standard Retention Times and MRM Transitions 
Analyte/Internal Retention Time MRM Transitions (m/z) 
Standard (min) Primary Secondary 
Alprazolam 3.697 309.30>281.00 309.30>205.00 
Clonazepam 3.463 315.80>270.00 315.80>214.00 
Diazepam 3.763 284.90>193.00 284.90>153.95 
Diphenhydramine 3.066 255.90>167.00 255.90>165.05 
Fentanyl 3.156 336.95>105.00 336.95>188.10 
Hydrocodone 2.577 299.90>198.90 300.00>171.00 
Nortriptyline 3.291 263.85>233.05 263.85>91.10 
Zolpidem 3.126 307.90>235.10 307.90>219.00 
    
Alprazolam-D5 3.691 314.10>285.95 314.10>210.00 
Clonazepam-D4 3.457 320.10>274.10 320.10>217.90 
Diazepam-D5 3.755 289.90>153.95 289.90>227.10 
Diphenhydramine-D3 3.080 259.00>167.00 258.90>152.00 
Fentanyl-D5 3.152 341.85>105.10 341.85>137.10 
Hydrocodone-D6 2.564 306.20>202.00 306.30>173.90 
Nortriptyline-D3 3.291 266.95>233.00 266.95>91.00 
Zolpidem-D6 3.127 314.20>235.10 314.00>236.10 
 
3.6 Validation 
 Validation procedures are aligned with the Scientific Working Group on Forensic 
Toxicology (SWGTOX) Standard Practices for Method Validation in Forensic Toxicology 
guidelines for qualitative confirmation/identification.54 SWGTOX guidelines do not establish 
exact specifications for qualitative methods; instead, the document passes responsibility to the 
laboratory to determine what is acceptable or significant.54 Definitions of validation parameters in 
the following sections were derived from those within the SWGTOX document. Methanol was 




3.6.1 Limit of Detection 
 The limit of detection (LOD) is defined as is the lowest concentration of an analyte that 
can be reliably differentiated from blank matrix and identified by the analytical method.54 
SWGTOX guidelines allow for an administratively-defined decision point to be selected for 
qualitative methods, even if a lower LOD is analytically possible.54 Low control solution was 
selected as the decision point for this portion of the validation. Low control solution was added to 
three separate unused patches at a volume of 100 μL per patch. Patches underwent the full 
extraction procedure and were injected in triplicate to ensure that all detection and identification 
criteria were met. Precision was calculated to determine variance among injections. 
3.6.2 Carryover 
 Carryover is defined as the appearance of unintended analyte signal in subsequent 
samples after the analysis of a positive sample.54 There was no possible cause of carryover during 
the extraction procedure as all items throughout the process were disposable. Therefore, only the 
LC/MS/MS was evaluated for carryover. High control solution at a volume of 100 μL and 
internal standard mix at a volume of 50 μL were added to a microcentrifuge vial. The 
concentrated solution was vortexed and transferred to an LC/MS/MS injection vial for analysis. 
The concentrated solution was injected three times, with each control injection followed 
immediately by a blank methanol injection. 
3.6.3 Matrix Effects 
 Properties of a matrix itself may interfere with extraction and detection. SMx™ artificial 
blank sweat, which contains 17 biological compounds in concentrations approximate to those in 
real sweat, was used to evaluate matrix effects. One mL of artificial blank sweat was added to an 
unused patch. In addition to the artificial sweat, a sweat patch with a wear time of 24 hr was 
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obtained from the preliminary study subject before dosing. The patches underwent the full 
extraction procedure and were analyzed to interpret potential matrix effects. 
3.6.4 Stable-Isotope Internal Standard Interference 
 Isotopically-labeled internal standards may contain non-labeled compounds as an 
impurity or have equivalent mass-to-charge ratios as ions of non-labeled compounds. In addition, 
non-labeled compounds may have similar effects on labeled internal standards. Stock internal 
standard mix was added at a volume of 50 μL to methanol at a volume of 100 μL in a 
microcentrifuge tube and vortexed. The solution was then transferred to an LC/MS/MS vial and 
analyzed for the presence of analyte ions. In a different microcentrifuge vial, 100 μL of high 
control solution was added with 50 μL of methanol and vortexed. The solution was then 
transferred to an LC/MS/MS vial and analyzed for the presence of internal standard. 
3.6.5 Analyte Interference 
 Interference of other commonly encountered compounds – including over-the-counter, 
prescription, and illicit drugs – is assessed to ensure that analytes in the method remain 
unaffected. A mixture of 64 compounds was produced in methanol at a concentration of 1000 
ng/mL of each compound. Medium control solution was added to four unused patches at a 
volume of 100 μL. Interference mix was added to two separate patches at a volume of 100 μL (for 
a total amount of 100 ng/patch of each interferent); the remaining two patches served as controls 
free of interference. All patches then underwent a full extraction procedure and LC/MS/MS 
analysis to interpret analyte interference. Each patch was injected in duplicate. Compounds in the 




Table 4. Interference Compounds 
6-acetylmorphine Doxepin JWH-200 Norhydrocodone 
7-aminoclonazepam Doxylamine JWH-250 Norpropoxyphene 
Acetaminophen Duloxetine MDA Oxazepam 
AM2201 Ethyl glucuronide Meperidine Oxycodone 
Amitriptyline Ethyl sulfate Meprobamate Pentazocine 
Amobarbital Fluoxetine Methamphetamine Peroxetine 
Amphetamine Flurazepam Methaqualone Propoxyphene 
Benzoylecgonine Heroin Methcathinone R-pseudoephedrine 
Brompheniramine HU-211 Methylphendiate Salicylic acid 
Caffeine Ibuprofen Midazolam Secobarbital 
Carbamazapine Imipramine Naloxone Tapentadol 
Carisoprodol JWH-018 Naltrexone Trazodone 
Chlorpheniramine JWH-019 Naproxen UR-144 
Cocaine JWH-073 Norbuprenorphine Venlofaxine 
Cotinine JWH-081 Nordiazepam Zaleplon 
CP 47, 497 JWH-122 Norfluoxetine Zolpiclone 
 
3.6.6 Storage Stability 
 The evaluation of sample stability in various conditions simulates what may be 
encountered in the processing of actual evidence. Medium control solution was added to seven 
unused patches at a volume of 100 μL per patch. One patch was immediately extracted and 
injected to serve as a reference. Remaining patches were placed into large test tubes. Two patches 
were stored in a freezer (-15°C), two patches were stored in a refrigerator (5°C), and two patches 
were left in the laboratory at room temperature (20°C). One patch from each storage condition 
was removed, extracted, and analyzed after 3 d. The remaining patches were removed, extracted, 





3.6.7 Autosampler Stability 
 In practice, samples may be reinjected from an autosampler in the hours and days after its 
initial run; therefore, an evaluation of sample stability in this environment is also practical to 
forensic laboratories. Medium control solution was added to an unused patch at a volume of 100 
μL. The patch underwent a full extraction and was injected immediately to serve as a reference. 
The sample was left in the autosampler at 4°C after the injection and was reinjected every 24 h 
for 7 d. 
3.7 Preliminary Study 
 Diphenhydramine at a dose of 50 mg was administered to a naïve subject following the 
submission of a pre-dose urine and sweat sample. A total of five patches were applied and 
removed at various times throughout the course of one week to simulate real-world use. Three 
unused sweat patches were applied to the subject’s upper right arm immediately after dosing. 
After 1 d and 3 d, one of the three original patches was removed and an unused patch was 
applied. After 7 d, all three remaining patches were removed. Urine samples were taken at 1 d, 3 
d, and 7 d after dosing and extracted using a method validated by the Oklahoma State University 
Forensic Trace & Toxicology Laboratory. Patch application and removal time frames as well as 
urine sampling times are displayed in Figure 1. All patches were applied and removed using the 
patch manufacturer’s application recommendations.  Once patches were removed, they were 
immediately extracted alongside a low control sample for comparison. Urine samples were 
compared to a urine control sample containing 7.5 ng/mL diphenhydramine. An exemption was 
obtained by the Oklahoma State University Institutional Review Board to complete this portion of 
the research, as a study with only one subject does not meet the generalizable knowledge 
component under the definition of human subject research. 
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Figure 1. Subject Patch Application and Removal Time Frames and Urine Sampling Times 
Patch #          
1          
2           
3         
4         
5         
Time 
Elapsed 
0 d 1 d 
 
3 d 
   
7 d 
Elapsed     
Urine #  1  2    3 
  
3.8 Data Analysis 
 Post-run data analysis was completed using Shimadzu LabSolutions software in Browser 
mode. Software was configured to automatically integrate and identify potential positive 
responses. All data was examined manually for the verification of true positives and negatives. 
Analyte identity was confirmed using the area ratios of prominent precursor and product ions. 
Analytes will be reported as positive if the calculated concentration is above the analyte’s LOD; a 
concentration below the analyte’s LOD will be reported negative. Identification criteria include 
the elution of a peak within ± 5 % of expected retention time and the presence of precursor-










4.1 Validation Data 
 Although lower LOD values were potentially achievable for some analytes, method 
LODs were set at the amounts present in low control patches to ensure proper detection and 
identification of all analytes. Retention time and precursor-product ion ratios were met for all 
nine injections. The imprecision values of each of the eight analytes in the method are displayed 
in Table 5.  











 Potential carryover responses were subject to identification criteria and were compared to 
LOD responses to assess the potential for a false positive. No carryover responses met 
identification criteria for any analyte in any of the three blank methanol injections.
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 Matrix effects were evaluated using artificial sweat and blank sweat from the preliminary 
study subject. The patch with artificial sweat did not behave in a similar manner to patches with 
real sweat during extraction and displayed response suppression for some internal standards 
during detection. In addition, matrix effect responses from artificial sweat exceeded 20% of the 
LOD for only one analyte, clonazepam, but did not meet identification criteria for any analyte. 
Matrix effects of blank sweat obtained from the preliminary trial did not exceed 20% of the LOD 
or meet identification criteria for any analyte. 
 Potential interferent responses of deuterated internal standard precursor or product ions 
into analyte precursor and product ions, or vice versa, were subject to identification criteria. 
Interferent areas were then compared to areas of the expected analyte or internal standard. Only 
one analyte (clonazepam) displayed interference with its respective internal standard, generating 
an internal standard area that was 0.3% of the analyte area. Only one internal standard (fentanyl-
D5) displayed interference with its respective analyte, generating an analyte area that was <0.1% 
of the internal standard area. All other potential interferent peaks of deuterated internal standard 
ions into analyte ions, or vice versa, did not meet identification criteria.  
 Potential interferent responses from patches fortified with other commonly-encountered 
toxicological compounds (see Table 4) were subject to identification criteria and compared to 
those of unfortified controls. Ratios of analyte area to internal standard area were then compared 
among interferent and non-interferent patches. In patches fortified with interference mix, 
retention time and precursor-product ion ratio identification criteria for all analytes and internal 
standards were met. However, area ratios varied from those at the same control concentration 
without interference mix. Area ratio interference is displayed in Table 6 as a percentage change 
from the unfortified control. In Table 6, a positive value indicates suppression of the target 
analyte and a negative value indicates enhancement.  
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Table 6. Analyte Interference from 64 Commonly-Encountered Toxicological Compounds 
Analyte Interference  
Alprazolam 25 % 
Clonazepam 19 % 
Diazepam 20 % 
Diphenhydramine 23 % 
Fentanyl 25 % 
Hydrocodone 17 % 
Nortriptyline -40 % 
Zolpidem 22 % 
  
 Storage stability was assessed by first ensuring that analyte responses in each sample met 
identification criteria. Ratios of analyte area to internal standard area in controls under the various 
storage conditions were then compared to the reference control. Identification criteria were met 
for each analyte in all stability samples. Area ratios of controls under various storage conditions 
are displayed in Table 7 for medium control patches and Table 8 for low control patches as 
percentages compared to the respective reference patch. The largest decay indicated is 30% but 









Alprazolam Clonazepam Diazepam Diphenhydramine 
Temperature Time 
-15°C 3 d 112 % 101 % 112 % 105 % 
7 d 110 % 104 % 107 % 103 % 
5°C 3 d 120 % 105 % 114 % 107 % 
7 d 114 % 104 % 111 % 104 % 
20°C 3 d 101 % 87 % 97 % 90 % 





Fentanyl Hydrocodone Nortriptyline Zolpidem 
Temperature Time 
-15°C 3 d 100 % 108 % 111 % 108 % 
7 d 108 % 107 % 99 % 100 % 
5°C 3 d 109 % 114 % 113 % 113 % 
7 d 111 % 110 % 101 % 100 % 
20°C 3 d 92 % 93 % 91 % 93 % 










Alprazolam Clonazepam Diazepam Diphenhydramine 
Temperature Time 
-15°C 3 d 89 % 86 % 89 % 86 % 
7 d 98 % 98 % 95 % 96 % 
5°C 3 d 93 % 84 % 91 % 86 % 
7 d 86 % 87 % 84 % 80 % 
20°C 3 d 98 % 89 % 93 % 86 % 





Fentanyl Hydrocodone Nortriptyline Zolpidem 
Temperature Time 
-15°C 3 d 91 % 89 % 89 % 88 % 
7 d 103 % 98 % 94 % 90 % 
5°C 3 d 93 % 88 % 87 % 90 % 
7 d 90 % 84 % 78 % 77 % 
20°C 3 d 97 % 91 % 84 % 89 % 
7 d 92 % 85 % 70 % 74 % 
 
 Autosampler stability responses were subject to identification criteria. Ratios of analyte 
area to internal standard area in each of the daily autosampler injections were then compared to 
that of the initial injection. Responses for each analyte in daily injections are displayed in Table 9 





Table 9. Autosampler Stability of Medium Control Sweat Patches at 4°C 
Storage 
Time 
Alprazolam Clonazepam Diazepam Diphenhydramine 
Time 
1 d 2% -8% 0% -3% 
2 d 1% -6% -2% 0% 
3 d -3% 1% -4% -5% 
4 d 2% 1% -3% -7% 
5 d 0% -6% -2% -3% 
6 d 1% -3% -4% -3% 
7 d -2% -5% -4% 4% 
Storage 
Time 
Fentanyl Hydrocodone Nortriptyline Zolpidem 
Time 
1 d 8% 4% -6% -5% 
2 d 3% 2% -5% -2% 
3 d 8% 0% -7% -9% 
4 d 8% 1% -9% -14% 
5 d -3% 3% -5% -3% 
6 d 6% 3% -7% -6% 
7 d -11% 1% -3% -3% 
 
4.2 Preliminary Study Data 
 The urine and sweat samples obtained from the subject prior to dosing were negative for 
all eight analytes in the panel. All five preliminary study sweat samples met identification criteria 
for diphenhydramine and registered an area ratio response greater than that of the LOD of 0.75 
ng/patch. Only urine sample 1, taken 24 hr after dosing, met identification criteria for 
diphenhydramine and registered an area ratio response greater than that of the 7.5 ng/mL control 
sample; subsequent samples were negative. Results are displayed in Figure 2; a plus sign (+) 
indicates a detected response above the LOD or control sample and a minus sign (-) indicates a 
detected response below the LOD or control sample. 
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Figure 2. Urine and Sweat Preliminary Study Data 
Patch #          
1 +        
2 +      
3 + 
4   + 
5     + 
Time 
Elapsed 
0 d 1 d 
 
3 d 
   
7 d 
Elapsed     
Urine #  1(+)  2(-)   3(-) 
 
4.3 Discussion 
 The extraction method described here is fairly straightforward and would be simple for 
an equipped forensic laboratory to implement. Few solutions are required for the extraction, but 
control solutions may be a challenge to make; blank sweat is difficult to obtain and artificial 
sweat may not accurately represent the physical and chemical properties of real sweat. Large 
batches are possible without much extra work, time, or resources per sample. The procedure does 
consume a moderate amount of methanol, but produces little waste for disposal due to the 
evaporation step. The destructive nature of the extraction process does not allow for a preliminary 
presumptive test unless part of the patch is cut or removed beforehand.  
 The qualitative LC/MS/MS method demonstrates high precision, sensitivity, and 
specificity. The administratively-defined cutoffs of 0.75 ng/patch for clonazepam, 
diphenhydramine, hydrocodone, nortriptyline, and zolpidem, and 3 ng/patch for alprazolam, 
diazepam, and fentanyl demonstrated identifiable responses and good precision. Carryover was 
not present in blank samples following the injection of concentrated controls.  
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 There was no prominent interference between deuterated internal standards and the 
respective analytes; however, interference was indicated with other commonly-encountered 
analytes. Although identification criteria were still met for all analytes, seven of the eight analytes 
experienced response suppression; the remaining compound, nortriptyline, experienced 
enhancement. These response changes can be attributed to increased or decreased ionization of 
target analytes caused by the interferent compounds. Specificity against common toxicological 
compounds was sufficient, but further method optimization to address interference should be 
conducted before the method is introduced in a forensic setting – especially if results are 
quantified.  
 Formal statistical comparison of stability effects and post-extraction degradation were not 
completed for these data sets due to the absence of explicit standards within the SWGTOX 
guidelines, but the variance displayed among controls in both studies are approximate to normal 
laboratory variance. Provided that samples are promptly stored in a refrigerator or freezer within 
a reasonable time frame and tested within days after extraction, stability of the analytes in the 
method does not present an issue. Overall, the methanol extraction and qualitative LC/MS/MS 
detection were successful. A quantitative method would be preferred if more definitive results are 
desired in future studies. 
 The outcomes from the preliminary study samples are perhaps the most important 
findings of this research. The positive detection of diphenhydramine in patches applied 
immediately after dosing was somewhat expected; however, positive detection in patches that 
were applied after a time delay was surprising. The cumulative sampling effect of patches 
appeared to influence presence of the analyte. Noting the substantial role that elapsed time plays 
in toxicological sample collection, this result warrants a meaningful conclusion: a noninvasive 
sampling technique was successful in determining the presence of a DFSA agent in a scenario 
similar to a delayed reporting.   
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 The comparison of diphenhydramine presence in sweat and urine samples further 
maintains the use of sweat as a specimen type for DFSA compound analysis. The urine sample 
collected three days after dosing displayed a detector response that met identification criteria, but 
did not exceed the LOD of 7.5 ng/mL. In contrast, the sweat patch that was applied three days 
after dosing was positive for diphenhydramine. One important factor to note is that a hydrolysis 
step was included in the urine extraction to convert phase II metabolites back to the parent 
compound, but no other diphenhydramine analogues or metabolites were included in this study. 
Still, these data suggest that sweat is actually more effective than urine at indicating the presence 
of diphenhydramine after some time has elapsed. Once again, the results generate the meaningful 







 DFSA prevalence cannot be accurately gauged and is likely underestimated. A clear 
definition of DFSA usable by all jurisdictions would establish a strong foundation for assessment. 
The approaches and methods of administration used by offenders can be examined to discover 
trends in drug acquisition and deployment. Similarly, studying DFSA behavior in traditional and 
unexpected settings can shed light on measures for prevention. Victim advocacy should be 
supported to make reporting as easy as possible and ensure that proper treatment is being given. 
Valuable evidence must be collected without exhaustive invasion to make allowances for the 
unique vulnerabilities of DFSA victims. 
 Currently, sweat patches are best suited as supplemental to other forms of confirmation 
testing, such as urine testing, in a DFSA setting. Although research has proved the emergence of 
drugs in sweat and manufacturers have designed a fairly efficient mechanism of sample 
collection, the nuances of the patch – such as external contamination, variability in sample 
volume, difficulty of quantitation, and lack of procedure standardization – preclude the device 
from being reliably standalone. 
 However, research can be completed to improve the utility of the patch. The mechanisms 
and pathways of drug distribution from the bloodstream to sweat glands and exterior layers of the 
skin must be investigated to better understand the various cofactors behind drug and metabolite  
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migration. Patches must be designed to facilitate movement and retention of sweat without 
reabsorption of analytes back onto the skin. Method development and optimization could expand 
the analyte panel to include more drug and metabolite compounds. Finally, research establishing 
a correlation of sweat concentration to blood concentration, urine concentration, or physiological 
symptoms must be conducted to give significant meaning to quantitation. 
 As this specimen type builds momentum with future research, standardization of methods 
and practices will be vital in maintaining consistency across industry and academia. In addition to 
the collection procedures mentioned earlier, other areas of laboratory analysis – such as sample 
extraction, instrument settings, and data interpretation – should be optimized specifically for 
sweat patches in order to obtain the highest level of accuracy, precision, and sensitivity for 
analyte detection. Steps taken by manufacturers like Pharmchem and international organizations 
like the U.N. Office on Drugs and Crime serve as solid foundations to establish more uniformity 
in the testing of these devices. If laboratories can prove to handle sweat patches effectively from 
sample collection to data analysis, the device will gain significant credibility toward 
independence. 
 This research demonstrated an effective qualitative method for the extraction and 
detection of eight common drug-facilitated sexual assault agents from sweat patches. In addition, 
one of the drug compounds – diphenhydramine – was detected in sweat after patch application in 
a preliminary study. As noninvasive and cumulative collection devices, sweat patches 
demonstrate characteristics that appeal to toxicologists and DFSA victims alike. Using trusted 
laboratory techniques, toxicologists should continue to work towards innovative applications in 
solving complex challenges to better serve law enforcement, the research community, and society 
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